NO165543C - Analogifremgangsmaate for fremst av terapeutisk aktiv (4r,5s,6s,8r,2's,-4's)-3- 4-(dimethylamino-carbonyl)-pyrrolidinhylthio -4-methyl-6-(1-hydroxyethyl)-1-azabicyclo- 3,2,0 hept-2-en-7-on-2-carboxylsyre i krystallinsk form. - Google Patents

Analogifremgangsmaate for fremst av terapeutisk aktiv (4r,5s,6s,8r,2's,-4's)-3- 4-(dimethylamino-carbonyl)-pyrrolidinhylthio -4-methyl-6-(1-hydroxyethyl)-1-azabicyclo- 3,2,0 hept-2-en-7-on-2-carboxylsyre i krystallinsk form.

Info

Publication number
NO165543C
NO165543C NO873205A NO873205A NO165543C NO 165543 C NO165543 C NO 165543C NO 873205 A NO873205 A NO 873205A NO 873205 A NO873205 A NO 873205A NO 165543 C NO165543 C NO 165543C
Authority
NO
Norway
Prior art keywords
pyrrolidinhylthio
hept
dimethylamino
promotion
hydroxyethyl
Prior art date
Application number
NO873205A
Other languages
English (en)
Norwegian (no)
Other versions
NO873205L (no
NO873205D0 (no
NO165543B (no
Inventor
Makoto Sunagawa
Yutaka Isobe
Yutaka Takeuchi
Haruki Matsumura
Tetsuo Noguchi
Yukio Ozaki
Original Assignee
Sumitomo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma filed Critical Sumitomo Pharma
Publication of NO873205D0 publication Critical patent/NO873205D0/no
Publication of NO873205L publication Critical patent/NO873205L/no
Publication of NO165543B publication Critical patent/NO165543B/no
Publication of NO165543C publication Critical patent/NO165543C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO873205A 1986-07-30 1987-07-30 Analogifremgangsmaate for fremst av terapeutisk aktiv (4r,5s,6s,8r,2's,-4's)-3- 4-(dimethylamino-carbonyl)-pyrrolidinhylthio -4-methyl-6-(1-hydroxyethyl)-1-azabicyclo- 3,2,0 hept-2-en-7-on-2-carboxylsyre i krystallinsk form. NO165543C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17932186 1986-07-30
JP15776987 1987-06-26

Publications (4)

Publication Number Publication Date
NO873205D0 NO873205D0 (no) 1987-07-30
NO873205L NO873205L (no) 1988-02-01
NO165543B NO165543B (no) 1990-11-19
NO165543C true NO165543C (no) 1991-02-27

Family

ID=26485103

Family Applications (2)

Application Number Title Priority Date Filing Date
NO873205A NO165543C (no) 1986-07-30 1987-07-30 Analogifremgangsmaate for fremst av terapeutisk aktiv (4r,5s,6s,8r,2's,-4's)-3- 4-(dimethylamino-carbonyl)-pyrrolidinhylthio -4-methyl-6-(1-hydroxyethyl)-1-azabicyclo- 3,2,0 hept-2-en-7-on-2-carboxylsyre i krystallinsk form.
NO1997013C NO1997013I1 (no) 1986-07-30 1997-10-17 Meropenem

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO1997013C NO1997013I1 (no) 1986-07-30 1997-10-17 Meropenem

Country Status (20)

Country Link
US (1) US4888344A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0256377B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2665767B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR243189A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU596857B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1322371C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3781980T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK172666B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2052524T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI88037C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3006254T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK169595A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU199473B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE60588B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL83372A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU88635I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX173359B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO165543C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ221224A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH24710A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1283906C (en) * 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
KR880006244A (ko) * 1986-11-24 1988-07-22 후지사와 도모 기찌 로 3-피롤리디닐티오-1-아자바이스클로[3.2.0]햅트2-엔-2-카르복실산 화합물 및 이의 제조방법
DE69019610D1 (de) * 1989-07-06 1995-06-29 Banyu Pharma Co Ltd Cyclische Derivate des Amidinylthiocarbapenems.
DE69013131T2 (de) * 1989-12-29 1995-05-24 Banyu Pharma Co Ltd 2-(2-Cyclopropylpyrrolidin-4-ylthio)carbapenemderivate.
TW264475B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
JP2696807B2 (ja) * 1992-08-06 1998-01-14 田辺製薬株式会社 カルバペネム誘導体の製法
GB9503717D0 (en) * 1995-02-24 1995-04-12 Smithkline Beecham Plc Novel compounds
FR2735474B1 (fr) * 1995-06-13 1997-08-08 Roussel Uclaf Chlorhydrate de zilpaterol sous une forme cristallisee particuliere, son procede de preparation et les produits intermediaires mis en oeuvre
YU37299A (sh) * 1997-02-07 2002-06-19 Kyoto Pharmaceutical Industries Ltd. Karbapenemsko jedinjenje, njegova primena i njegovo intermedijarno jedinjenje
WO1999057121A1 (fr) 1998-05-01 1999-11-11 Kyoto Pharmaceutical Industries, Ltd. Derives de carbapenem, son utilisation et composes intermediaires a base de carbapenem
JP4130078B2 (ja) 1999-06-03 2008-08-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 カルバペネム誘導体結晶と注射製剤
US7041660B2 (en) 1999-07-06 2006-05-09 Sankyo Company, Limited Crystalline 1-methylcarbapenem derivatives
TWI250160B (en) * 1999-07-06 2006-03-01 Sankyo Co Crystalline 1-methylcarbapenem compound
EP1762236B1 (en) 2000-05-12 2015-07-15 Septodont Holding SAS Formulations of alpha adrenergic receptor antagonists and their uses
JP5079190B2 (ja) * 2001-04-27 2012-11-21 大日本住友製薬株式会社 アゼチジノン誘導体およびその製造方法
HUP0400444A3 (en) * 2001-05-21 2007-02-28 Kyoto Pharmaceutical Ind Carbapenem compound, pharmaceutical compositions containing them and their use
KR100451672B1 (ko) * 2001-06-05 2004-10-08 한미약품 주식회사 결정성 세프디니르 산부가염, 이의 제조방법 및 이를이용한 세프디니르의 제조방법
US20040198973A1 (en) * 2001-08-13 2004-10-07 Tsujii Masahiko Process for preparation of carbapenem antibiotics
USRE40794E1 (en) 2001-09-26 2009-06-23 Merck & Co., Inc. Crystalline forms of carbapenem antibiotics and methods of preparation
ATE518864T1 (de) * 2001-09-26 2011-08-15 Merck Sharp & Dohme Verfahren zur herstellung von carbapenemverbindungen
ITMI20012364A1 (it) * 2001-11-09 2003-05-09 Antibioticos Spa Processo di sintesi della cefixima via alchil-o arilsolfonati
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
US20030236306A1 (en) * 2002-06-20 2003-12-25 Chen Andrew X. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
US7229630B2 (en) * 2002-06-20 2007-06-12 Novalar Pharmaceuticals, Inc. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
WO2004024185A1 (ja) 2002-09-11 2004-03-25 Michio Ishibashi 医薬または化粧料
ATE518865T1 (de) * 2004-06-02 2011-08-15 Sandoz Ag Meropenem-zwischenprodukt in kristalliner form
WO2006035300A2 (en) * 2004-09-30 2006-04-06 Ranbaxy Laboratories Limited A process for the preparation of meropenem
JP4547245B2 (ja) * 2004-12-16 2010-09-22 株式会社パーマケム・アジア ペリンドプリルエルブミンのｉ型結晶、及びその製造方法
US8501818B2 (en) * 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
US7872050B2 (en) * 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US20110039943A1 (en) * 2005-03-14 2011-02-17 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
US20070197781A1 (en) * 2005-07-29 2007-08-23 Neera Tewari Processes for the preparation of carbapenems
PT1926732E (pt) 2005-09-05 2013-12-27 Ranbaxy Lab Ltd Processo para a preparação de compostos de carbapenem
JP5247449B2 (ja) 2005-09-15 2013-07-24 オーキッド ケミカルズ アンド ファーマシューティカルズ リミテッド β−ラクタム系抗生物質の改善された調製方法
CN100497338C (zh) * 2006-01-05 2009-06-10 上海医药工业研究院 4－甲基－7－氧－1－氮杂双环[3.2.0]庚－2－烯－2－羧酸类衍生物的制备方法
KR100781821B1 (ko) * 2006-02-16 2007-12-03 문순구 카르바페넴계 화합물의 제조방법
WO2007111328A1 (ja) * 2006-03-28 2007-10-04 Kaneka Corporation カルバペネム化合物の改良された製造方法
KR20090007572A (ko) * 2006-04-28 2009-01-19 카네카 코포레이션 카르바페넴 항생 물질 중간체의 개량된 정석 방법
EP2229944A1 (en) * 2007-12-12 2010-09-22 Dainippon Sumitomo Pharma Co., Ltd. Preparation composition
US20090216010A1 (en) * 2008-02-22 2009-08-27 Wei-Hong Tseng Crystalline carbapenem compound and produced method thereof
EP2098525A1 (en) 2008-02-26 2009-09-09 Savior Lifetec Corporation Crystalline carbapenem compound and produced method thereof
DK3494960T3 (da) * 2008-03-27 2021-01-25 Helsinn Healthcare Sa Stabiliserede sammensætninger af alkyleringsmidler og fremgangsmåder til anvendelse af samme
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
KR20110049823A (ko) * 2008-07-30 2011-05-12 랜박시 래보러터리스 리미티드 카르바페넴 화합물의 제조 방법
ES2477290T3 (es) 2009-03-13 2014-07-16 Daewoong Pharmaceutical Co., Ltd. Método mejorado para preparar meropenem usando polvo de zinc
WO2011048583A1 (en) 2009-10-23 2011-04-28 Ranbaxy Laboratories Limited Process for the preparation of carbapenem compounds
WO2011141847A1 (en) * 2010-05-10 2011-11-17 Orchid Chemicals And Pharmaceuticals Limited An improved process for the preparation of meropenem
WO2012052978A1 (en) 2010-10-22 2012-04-26 Ranbaxy Laboratories Limited A process for the preparation of pure meropenem trihydrate
CN101962383A (zh) * 2010-11-12 2011-02-02 上海巴迪生物医药科技有限公司 一种美罗培南的合成方法
WO2012081033A2 (en) * 2010-12-06 2012-06-21 Sequent Scientific Limited A process for preparation of imipenem
CN102532140B (zh) * 2010-12-21 2015-03-11 北大方正集团有限公司 一种美罗培南三水合物的制备方法
CN102250096B (zh) * 2011-09-05 2016-04-06 江西华邦药业有限公司 一种美罗培南的制备方法
CN103570720B (zh) * 2012-07-31 2016-02-10 新乡海滨药业有限公司 一种美罗培南原料药、其制备方法及包含其的药物组合物
CN103570718B (zh) * 2012-07-31 2016-06-29 深圳市海滨制药有限公司 一种美罗培南原料药、其制备方法及包含其的药物组合物
CN103570719B (zh) * 2012-07-31 2016-03-02 深圳市海滨制药有限公司 一种美罗培南原料药、其制备方法及包含其的药物组合物
KR101331762B1 (ko) 2012-12-28 2013-11-20 주식회사 대웅제약 메로페넴의 삼수화물의 제조방법
CN103044429B (zh) * 2013-01-28 2015-04-01 苏州二叶制药有限公司 一种美罗培南的制备方法
ES2835398T3 (es) 2013-02-01 2021-06-22 Ocuphire Pharma Inc Métodos y composiciones para la administración oftálmica diaria de fentolamina para mejorar el rendimiento visual
ES2762153T3 (es) 2013-02-01 2020-05-22 Ocuphire Pharma Inc Soluciones oftálmicas acuosas de fentolamina y usos médicos de las mismas
KR102144777B1 (ko) 2013-06-19 2020-08-18 제이더블유중외제약 주식회사 결정형 메로페넴 삼수화물의 제조방법
CN106459052B (zh) * 2014-03-27 2021-07-30 庄信万丰股份有限公司 制备碳青霉烯抗生素的方法
WO2020081562A1 (en) 2018-10-15 2020-04-23 Ocuphire Pharma, Inc. Methods and compositions for treatment of glaucoma and related conditions
SG11202104094YA (en) 2018-10-26 2021-05-28 Ocuphire Pharma Inc Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK153486C (da) * 1978-07-03 1988-11-28 Merck & Co Inc Analogifremgangsmaade til fremstilling af krystallinsk n-formimidoyl-thienamycin-monohydrat
EP0113101A1 (en) * 1982-12-30 1984-07-11 Merck & Co. Inc. 6-(1-Hydroxyethyl)-2-SR8-1-methyl-1-carbadethiapen-2-em-3-carboxylic acid esters
CA1283906C (en) * 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
JPS60104088A (ja) * 1983-11-11 1985-06-08 Sumitomo Chem Co Ltd 新規なβ−ラクタム化合物およびその製造法
US4748238A (en) * 1984-03-14 1988-05-31 Merck & Co., Inc. Crystalline 1R,5S,6S,8R-1-methyl-2-(N,N-dimethylcarbamimidoylmethylthio)-6-(1-hydroxyethyl)-1-carbapen-2-em-3-carboxylic acid
US4713451A (en) * 1984-04-09 1987-12-15 Merck & Co., Inc. Crystalline dimethyliminothienamycin
US4761408A (en) * 1984-11-02 1988-08-02 Ciba-Geigy Corporation Crystalline aminomethyl compound
NZ214691A (en) * 1984-12-27 1988-08-30 Sumitomo Pharma The preparation of carbapenem derivatives and beta-lactam intermediates
US4788282A (en) * 1985-06-07 1988-11-29 Bristol-Myers Company Deprotection of allylic esters and ethers

Also Published As

Publication number Publication date
IL83372A0 (en) 1987-12-31
NO1997013I1 (no) 1997-10-17
FI88037B (fi) 1992-12-15
FI88037C (fi) 1993-03-25
IE60588B1 (en) 1994-07-27
GR3006254T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-06-21
MX7534A (es) 1993-10-01
EP0256377A1 (en) 1988-02-24
AR243189A1 (es) 1993-07-30
DK399087A (da) 1988-01-31
NO873205L (no) 1988-02-01
EP0256377B1 (en) 1992-09-30
LU88635I2 (fr) 1995-12-01
IL83372A (en) 1992-05-25
JP2665767B2 (ja) 1997-10-22
ES2052524T3 (es) 1994-07-16
DK172666B1 (da) 1999-05-10
DK399087D0 (da) 1987-07-30
US4888344A (en) 1989-12-19
PH24710A (en) 1990-10-01
DE3781980D1 (de) 1992-11-05
FI873299L (fi) 1988-01-31
FI873299A0 (fi) 1987-07-29
HK169595A (en) 1995-11-10
NO873205D0 (no) 1987-07-30
AU7619687A (en) 1988-03-03
DE3781980T2 (de) 1993-02-18
NO165543B (no) 1990-11-19
NZ221224A (en) 1989-10-27
AU596857B2 (en) 1990-05-17
CA1322371C (en) 1993-09-21
IE871959L (en) 1988-01-30
JPS6434986A (en) 1989-02-06
MX173359B (es) 1994-02-23
HU199473B (en) 1990-02-28
HUT44553A (en) 1988-03-28

Similar Documents

Publication Publication Date Title
NO165543C (no) Analogifremgangsmaate for fremst av terapeutisk aktiv (4r,5s,6s,8r,2's,-4's)-3- 4-(dimethylamino-carbonyl)-pyrrolidinhylthio -4-methyl-6-(1-hydroxyethyl)-1-azabicyclo- 3,2,0 hept-2-en-7-on-2-carboxylsyre i krystallinsk form.
NO170480C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenoksyeddiksyre-derivater
NO168770C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater
NO163406C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazokinolinonderivater.
NO168303C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heterocyklyloksoftalazinyl-eddiksyre-derivater
NO862477D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-arylimidazol-derivater.
NO172343C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive askorbinsyrederivater
NO170629C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive dikloranilin-derivater
NO862956L (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrimidin-derivater.
NO167916C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiolaktam-n-eddiksyrederivater
NO169438C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tetrazolforbindelser
NO170976C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenylbuten-syrederivater
NO162155C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive vinylkarbonoksylsyrederivater.
NO168299C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive alkansulfonanilid-derivater
NO863373L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
NO169069C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3-alkoksy-2-aminopropylaminderivater
NO165069C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cyklopentyletere.
NO891114D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive arakidonsyre-derivater.
NO171108C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3-desmetyl-mevalonsyrederivater
NO171211C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksaner
NO164895C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive dikloranilinderivater.
NO168103C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aralkylimidazolderivater
NO171499C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5,6-dihydro-4h-cyklo-penta(b)tiofen-6-karboksylsyre-derivater
NO167801C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,2'-bi-1h-imidazolderivater.
NO166322C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive nitroapovincaminsyrederivater.

Legal Events

Date Code Title Description
MK1K Patent expired